466 results on '"Anwer, Faiz"'
Search Results
2. Efficacy of low-dose direct oral anticoagulants (DOACs) for venous thromboembolism prophylaxis in newly diagnosed multiple myeloma.
3. Characterizing clinical trials for CAR T targeting solid tumors from 2018 to 2023: A systematic review.
4. Trends in hospice utilization and place of death preferences in multiple myeloma-related deaths from 2003 to 2020: Analysis of CDC Wonder database.
5. Association between social determinants of health and time to treatment for newly diagnosed multiple myeloma.
6. Evaluating ChatGPT as an educational resource for patients with multiple myeloma: A preliminary investigation
7. Role of Palliative Care in the Supportive Management of AL Amyloidosis—A Review
8. Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management
9. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
10. Incidence, Characteristics, and Management of Adverse Events with Bispecific T Cell Engagers for Relapsed or Refractory Multiple Myeloma: A Systematic Review
11. The TACTUM23 Study: Access to Cellular Therapies in Multiple Myeloma: Perspectives of Treating Versus Referring Physicians in 2023
12. Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma-1 Trial Eligibility Criteria: A Real-World Multicenter Study from the US Myeloma Innovations Research Collaborative (USMIRC)
13. A Multicenter Experience: Duration of Mandatory CRS and Icans Monitoring for Myeloma and Lymphoma CAR-T Recipients
14. Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
15. Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin's Lymphoma (NHL) and Multiple Myeloma (MM) Treated with CAR T-Cell Therapies.
16. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience from the US Myeloma Innovations Research Collaborative (USMIRC)
17. Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A Real-World Experience of the US Myeloma Innovations Research Collaborative (USMIRC)
18. Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa‐1 trial eligibility criteria: A real‐world multicentre study
19. Incidence and Risk of Secondary Malignancy in Patients with Waldenström Macroglobulinemia: A Population-Based Analysis
20. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
21. Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
22. Association of Patient Characteristics and Insurance Type with Multiple Myeloma Care Patterns
23. Analysis of risk factors and prognostic factors of brain metastasis in gastric cancer: a surveillance, epidemiology and end-results database study
24. Validation of the GATMO score in predicting non‐relapse mortality following hematopoietic cell transplant in multiple myeloma patients
25. The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma
26. P-330 The third-generation genetic engineered mouse model of late-stage multiple myeloma
27. POSTER: MM-255 Advances in CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-analysis of Clinical Trials in the Last Two Years
28. P-256 Initial report of a single institution experience with teclistamab for relapsed or refractory multiple myeloma including prior BCMA
29. MM-255 Advances in CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials in the Last Two Years
30. P-320 Iberdomide (IBER) plus dexamethasone (DEX) in patients with relapsed/refractory multiple myeloma (RRMM): a safety analysis from the CC-220-MM-001 trial
31. Beyond monoclonal gammopathy of undetermined significance, clinical spectrum of immunoglobulin M gammopathy: a case series with focus on the diagnostic and management challenges
32. P-465 Global disparities in multiple myeloma: examining adverse events and drug toxicity trends
33. Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review
34. Clinical Research in Chronic Lymphocytic Leukemia in Pakistan; A Systematic Review
35. Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma
36. Ocular complications of antineoplastic therapies
37. Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
38. The Association of Body Composition and Outcomes Following Autologous Hematopoietic Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma
39. Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials
40. The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review
41. Intravenous immunoglobulin prophylaxis is associated with decreased rate of infection‐related hospitalizations in multiple myeloma patients
42. Liquid biopsies and minimal residual disease in myeloid malignancies
43. Systemic AL amyloidosis: current approach and future direction
44. Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
45. Total Body Irradiation Versus Chemotherapy Conditioning in Pediatric Acute Lymphoblastic Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant: A Systematic Review and Meta-Analysis
46. Ethical Challenges in CAR-T slot allocation
47. Fig S1 from Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury
48. Data from Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury
49. Supplementary Data from Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury
50. Fig S1 from Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.